Shanghai Chest Hospital, China's first specialist chest hospital (1957), performs one of the world's largest volumes of lung and oesophageal operations and houses the Shanghai Lung Cancer Center; its investigators led the Chinese registration trials of EGFR, ALK and ROS1 inhibitors.
Founded in 1957 as China's first specialist chest hospital, Shanghai Chest performs one of the largest volumes of lung and oesophageal operations in the world each year and houses the Shanghai Lung Cancer Center directed by Shun Lu. Its investigators have led Chinese registration trials of EGFR, ALK and ROS1 inhibitors and PD-1 combinations, and contributed to the global osimertinib, lorlatinib and amivantamab programmes. Thoracic surgery, oesophageal cancer, thymic tumours and interventional bronchoscopy are core strengths, with robotic and uniportal video-assisted surgery widely used. The hospital is a national clinical research centre for respiratory disease.
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-16.
Matched to Shanghai Chest Hospital, including child institutions. 539 works · 6,491 citations · 69% open access · 21% clinical trials · 1% reviews.
Shares Lorlatinib, RET, ALK, Osimertinib.
Shares ALK, Robotic & minimally invasive surgery, EGFR, Small-cell lung cancer.
Shares Amivantamab, Osimertinib, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Amivantamab, MET, Osimertinib, EGFR.
Shares Amivantamab, MET, Osimertinib, EGFR.
Shares Lorlatinib, ALK, Osimertinib, EGFR.